SCHEMBL30459527

SCHEMBL30459527

Cc1nc2c(F)cc(-c3nc(Nc4ccc(N5CCC(N6CCNCC6)CC5)cn4)ncc3F)cc2n1C(C)C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 16/20 0.62
CDK1 P06493 13/20 0.62
CCNB1 P14635 7/20 0.62
CCNE1 P24864 7/20 0.62
CDK6 Q00534 12/20 0.62
CCND3 P30281 11/20 0.62
CCNA2 P20248 6/20 0.62
CDK2 P24941 4/20 0.60
CDK9 P50750 3/20 0.60
CDK7 P50613 2/20 0.60
CCNT1 O60563 2/20 0.60
EGFR P00533 2/20 0.59
CCNE2 O96020 2/20 0.59
PIM1 P11309 2/20 0.59
CIT O14578 1/20 0.59
GAK O14976 1/20 0.59
DYRK3 O43781 1/20 0.59
STK16 O75716 1/20 0.59
CCNK O75909 1/20 0.59
STK10 O94804 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17489268 1.00 CDK4 (0.62) CDK4CDK1CCNB1CCNE1CDK6
SCHEMBL17489251 0.94 CDK4 (0.60) CDK4CDK1CCNB1CCNE1CDK6
SCHEMBL30459609 0.93 CDK6 (0.69) CDK4CDK1CCNB1CCNE1CDK6
SCHEMBL30459608 0.93 CDK6 (0.69) CDK4CDK1CCNB1CCNE1CDK6
SCHEMBL17488831 0.93 CDK6 (0.69) CDK4CDK1CCNB1CCNE1CDK6
SCHEMBL17477178 0.92 CDK4 (0.69) CDK4CDK1CCNB1CCNE1CDK6
SCHEMBL17489168 0.90 CDK4 (0.72) CDK4CDK1CCNB1CCNE1CDK6
SCHEMBL17488770 0.90 CDK4 (0.64) CDK4CDK1CCNB1CCNE1CDK6
SCHEMBL17489148 0.89 CDK4 (0.71) CDK4CDK1CCNB1CCNE1CDK6
SCHEMBL17488701 0.88 CDK4 (0.64) CDK4CDK1CCNB1CCNE1CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4446324-A1 LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2024-10-16 EP disclosed
WO-2023104155-A1 LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF 标新生物医药科技(上海)有限公司 2023-06-15 WO disclosed